MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 clinical trials in Korea2021/12/24STEM CELL THERAPEUTIC
MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/10/27STEM CELL THERAPEUTIC
MEDIPOST requests approval for the phase 2 clinical trial in Korea of its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/07/30STEM CELL THERAPEUTIC
MEDIPOST presents the development progress of its next-generation injectable drug for knee osteoarthritis in the Spring Conference of the Korean Orthopedic Surgeons Association2021/07/09STEM CELL THERAPEUTIC
MEDIPOST completes the expansion of its GMP facilities for CARTISTEM, a stem cell therapy, and SMUP-IA-01, an injectable knee osteoarthritis treatment2021/05/17STEM CELL THERAPEUTIC
MEDIPOST speeds up its global commercialization of CARTISTEM by requesting official product approval in Malaysia2021/03/15STEM CELL THERAPEUTIC
MEDIPOST receives approval for processing the phase 3 clinical trial of CARTISTEM in Japan2021/02/15STEM CELL THERAPEUTIC
MEDIPOST’s CEO Dr Yang Yoonsun Named on the Forbes 2020 List of Asia’s Power Businesswomen2020/09/16MEDIPOST
MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan2019/12/09STEM CELL THERAPEUTIC
MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Treatment of Osteochondral Cartilage Defects in Ankle Joint2019/12/03STEM CELL THERAPEUTIC
MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTISTEM and new pipeline of products2019/11/14STEM CELL THERAPEUTIC